How Analysts Feel About Amicus Therapeutics, Inc. (NASDAQ:FOLD)?

January 18, 2018 - By Linda Rogers

 How Analysts Feel About Amicus Therapeutics, Inc. (NASDAQ:FOLD)?
Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It improved, as 16 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported.
Bnp Paribas Arbitrage has 19,357 shares. Proshare Advsrs Lc has 104,050 shares for 0.01% of their portfolio. Wellington Mgmt Group Limited Liability Partnership has 6.06M shares for 0.02% of their portfolio. Smith Asset Management Group L P owns 31,400 shares or 0.02% of their US portfolio. Cornerstone Cap Mngmt Ltd Liability Co stated it has 68,532 shares or 0.01% of all its holdings. Amer International Group has 109,628 shares for 0.01% of their portfolio. Amalgamated Financial Bank reported 21,017 shares. Tiaa Cref Investment Mngmt Limited holds 0.01% or 550,188 shares in its portfolio. Us Bancshares De holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 813 shares. Mckinley Mngmt Ltd Delaware stated it has 0.07% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Massachusetts Financial Services Ma reported 676,117 shares. The United Kingdom-based Barclays Public Limited Co has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Nationwide Fund holds 0.01% or 178,212 shares. Massachusetts-based Geode Cap Ltd Llc has invested 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Sectoral Asset Management, Quebec – Canada-based fund reported 2.41 million shares.

Since October 12, 2017, it had 0 insider purchases, and 14 sales for $10.19 million activity. Crowley John F sold $1.06M worth of stock. Barth Jay sold 5,000 shares worth $73,559. $140,490 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by RAAB MICHAEL. 20,000 shares were sold by HAYDEN DONALD J JR, worth $300,002. Baird William D III had sold 40,000 shares worth $570,132 on Thursday, October 12. Do Hung also sold $715,360 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, October 12.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 20 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Buy” on Sunday, August 13. The rating was initiated by Robert W. Baird with “Neutral” on Thursday, April 14. The firm has “Buy” rating given on Tuesday, August 18 by Zacks. On Sunday, June 25 the stock rating was maintained by Cowen & Co with “Buy”. As per Tuesday, September 8, the company rating was maintained by JP Morgan. The firm has “Buy” rating given on Monday, August 7 by Cowen & Co. The firm has “Outperform” rating by Robert W. Baird given on Wednesday, July 12. Leerink Swann maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Monday, August 31 with “Buy” rating. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Neutral” rating by Chardan Capital Markets on Wednesday, September 16. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 11 report. Below is a list of Amicus Therapeutics, Inc. (NASDAQ:FOLD) latest ratings and price target changes.

04/10/2017 Broker: Leerink Swann Rating: Buy New Target: $20.0
13/09/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $16.5
13/08/2017 Broker: Cowen & Co Rating: Buy New Target: $16.0000 Maintain
07/08/2017 Broker: Cowen & Co Rating: Buy New Target: $16.0000 Maintain

The stock increased 2.34% or $0.37 during the last trading session, reaching $16.15. About 2.45 million shares traded or 6.56% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since January 18, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company has market cap of $2.69 billion. The Company’s principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. It currently has negative earnings. The firm is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease.

More recent Amicus Therapeutics, Inc. (NASDAQ:FOLD) news were published by: Globenewswire.com which released: “Amicus Therapeutics Launches Galafoldâ„¢ (Migalastat) for Treatment of Fabry …” on January 17, 2018. Also Zacks.com published the news titled: “Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher January 11, 2018” on January 11, 2018. Globenewswire.com‘s news article titled: “Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial …” with publication date: January 08, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.